Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

hat had previously shown limited utility for patients with myelofibrosis.

Myelofibrosis is a chronic malignant blood disorder commonly caused by mutations in the JAK2 pathway (which normally signals the body to create blood cells), including most commonly the JAK2 V617F mutation. This mutation leads to the overproduction of scar tissue in the bone marrow and shifts red and white blood cells and platelets from the bone marrow into the spleen and liver, enlarging the organs and leading to anemia, infection, inflammation, and easy bleeding and bruising.

The first approved treatment for myelofibrosis is ruxolitinib, a therapy that targets the JAK2 mutation by blocking the action of all JAK-related genes in the body, including those from both healthy and diseased cells. However, clinical results have been modest to date. In particular, resistance to JAK inhibitors has been associated with an increase in JAK2 levels, which leads to continued JAK2 activity despite ruxolitinib treatment. This resistance can be reversed by inhibiting heat shock protein 90 (HSP 90), which destabilizes JAK2 and reduces JAK2 protein levels. Since cancer cells are continually dividing, they constantly burden the cell system and depend on HSP90 function to allow the JAK2 protein to maintain cancer cells' function and growth.

Recognizing HSPs as a potential target for treatment, researchers have recently explored the possibility of blocking HSP90 to treat blood cancers. Unlike ruxolitinib, which blocks the function of the abnormal JAK2 protein that maintains the function of the cancerous cell, HSP90 inhibitors block the function of HSP90 in the cells. This allows for the breakdown of the JAK2 protein and weakens the cell's ability to grow and divide, allowing it to become sensitive to treatment. PU-H71, a HSP90 inhibitor, previously shown to have efficacy in different cancer cells and animal models including myelofibrosis, is currently undergoing Phase I clinical trials
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The global digital PCR (dPCR) and qPCR market is expected ... 2014 to 2019. , The global digital PCR (dPCR) and qPCR ... 2014 to 2019. Although the mature markets such as the U.S., ... (dPCR) and qPCR market the Asia-Pacific region is expected to grow ... growth of the digital PCR (dPCR) and qPCR market is driven ...
(Date:3/5/2015)... Shania Twain will be touring throughout ... She has hinted that this will be her final tour ... one last time. She has had a residency in Las ... has millions of loyal fans around the world. After opening ... and on June 30th she will be at Madison Square Garden ...
(Date:3/5/2015)... March 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread ... of eco-friendly building materials made primarily from bamboo, ... testing all their flooring products for volatile organic ... Benchmark International (BMH). Results from formaldehyde ...
(Date:3/5/2015)... March 05, 2015 A Bakersfield, Calif. state ... seven-week trial awarding the plaintiff Coleen M. Perry a ... result of a TVT-Abbrevo pelvic mesh sling device, manufactured by ... Tom Cartmell , a partner at Wagstaff & Cartmell ... for the plaintiff, along with Rich Freese and Tim Goss ...
(Date:3/5/2015)... March 05, 2015 AxoGen, Inc. ... on the peripheral nerve repair market, reported record revenue ... 31, 2014 compared to $2.98 million in the year-ago ... growth strategies. , “Our strong fourth quarter revenue ... nerve repair products which is driving increased surgeon adoption ...
Breaking Medicine News(10 mins):Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... worlds largest publisher of open access journals, is ... Magnetic Resonance (JCMR) is moving to BioMed Centrals ... publishers, Taylor & Francis. The move from a ... Society of Cardiovascular Magnetic Resonance (SCMR) members and ...
... OCALA, Fla., Dec. 12 Franck,s Compounding Lab ... Pharmacy Services in,Woodruff, Wisconsin. Island Pharmacy owners, Randy ... other personal interests. Selling their,pharmacy to Franck,s Compounding ... ensure the continuance of high quality prescriptions and ...
... up with community based, organizations and Babies "R" Us to help ... ... little ones, MERRILLVILLE, Ind., Dec. 12 With a traditional ... afternoon when,Anthem Blue Cross and Blue Shield hosts a community-wide baby ...
... fighting gum disease , , WEDNESDAY, Dec. 12 (HealthDay ... infections, and a weakened immune response may be to ... , In experiments with mice infected with the bacteria ... to battle gum infection than their normal-weight counterparts, according ...
... Austria, December 12 f-star, an antibody,engineering company ... unique Modular Antibody Technology, announced today that it,has ... three,outstanding scientists to form the nucleus of this ... Professor Sir Ravinder Maini, Imperial College, London, ...
... organizations in ... underserved areas, WOODLAND HILLS, Calif., Dec. 11 ... $30,000 in end of,year donations to various food banks throughout California. An ... and,southern California to assist vulnerable populations., Blue Cross employees will visit ...
Cached Medicine News:Health News:Society of Cardiovascular Magnetic Resonance chooses open access 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 3Health News:Obesity Weakens Immune Response 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2
(Date:3/5/2015)...   MeridianRx earned highest possible score ... leading indicators during its recent URAC accreditation review ... very proud of earning this level of accreditation ... Operating Officer of MeridianRx. "It is a testament ... flexibility and innovation." URAC,s leading indicators ...
(Date:3/5/2015)... 2015 BioLineRx (NASDAQ: BLRX ... to identifying, in-licensing and developing promising therapeutic candidates, ... public offering of American Depositary Shares ("ADSs"), each ... of the ADSs in the offering are to ... Securities is acting as sole book-running manager for ...
(Date:3/5/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... therapeutics including high value and difficult to manufacture ... full year 2014 financial results will be released ... opens for trading.  At 9:00 am Eastern Time, ... discuss the financial results and provide a business ...
Breaking Medicine Technology:MeridianRx Earns Highest URAC Accreditation Status 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2
... Company to Submit a Supplemental New Drug Application to ... Cephalon, Inc . (Nasdaq: CEPH ... clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as a ... Based on these findings, Cephalon(R) will file a ...
... today announced that the Endocrinologic and Metabolic Drugs Advisory Committee ... finalized its discussions of questions related to liraglutide, a once-daily ... to the risk profile of liraglutide. , , ... A majority of Advisory Committee members supported that appropriate evidence ...
Cached Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 2Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 3
... Ziemer's FEMTO LDV, the first compact, mobile ... provide a versatile, powerful platform for a ... The basic system addresses the demand of ... that is consistent with an efficient LASIK ...
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Medicine Products: